

Conference Programme - Day One: Wednesday 24th February 2021

09:00 - 09:10	Welcome to BSG 2021 Mr Andrew Hayes, President, British Sarcoma Group
09:10 - 09:55	SESSION 1: Immuno-oncology in Sarcoma CHAIR: Robin Jones
09:10 - 09:27	Facts and Hopes of Immunotherapy for Sarcomas - Dr Javier Martin-Broto, Institute of Biomedicine of Seville University Sevilla
09:27 - 09:44	Combination therapy and immune-based classification of sarcomas - Dr Maude Toulmonde, l'Institut Bergonié, Bordeaux
09:44 - 09:55	Questions and Discussion
10:00 - 11:00	SESSION 2: Clinical Trials Update CHAIR: Beatrice Seddon
10:00 - 10:10	Introduction and overview - Prof Bernadette Brennan, Royal Manchester Childrens Hospital
10:10 - 10:20	Update on STRASS2 - Mr Dirk Strauss, Royal Marsden Hospital
10:20 - 10:30	Update on ICONIC - Dr Sandra Strauss, University College London Hospitals
10:30 - 10:40	IMRiS trial results - Dr Beatrice Seddon, University College London Hospitals
10:40 - 10:50	EuroEwings 2012 trial results - Prof Bernadette Brennan, Royal Manchester Childrens Hospital
10:50 - 11:00	Questions and Discussion
11:00 - 11:30	Morning break and poster viewing
11:30 - 12:30	SESSION 3: Proffered Papers - Oncology CHAIR: Ian Judson
11:30 - 11:37	Long-term efficacy, tolerability, and overall survival in patients with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase 1 trial update - Robin Jones, Royal Marsden Hospital and Institute of Cancer Research
11:37 - 11:44	Final analysis of the Phase 1 trial of NY-ESO-1-specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS) - Sandra D'Angelo, Memorial Sloan Kettering Cancer Center, New York, NY, USA
11:44 - 11:51	Incidence and Outcome of Breast Sarcomas in NHS England (2013-2018): An Analysis from Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS) - Mahbubl Ahmed, University College Hospital, London
11:51 - 11:58	Myxoid Liposarcoma: Evaluation of Response to Radiotherapy, Surgical and Clinical Outcomes at the Royal Marsden Sarcoma Unit between 1990-2018 - Yolanda Augustin, Royal Marsden Sarcoma Unit
11:58 - 12:05	Preoperative versus postoperative radiotherapy for extremity soft-tissue sarcoma – A systematic review and meta-analysis of long-term survival - Garikai Kungwengwe, The Welsh Centre for Burns and Plastic Surgery
12:05 - 12:12	Durable Response to Serial Tyrosine Kinase Inhibitors (TKIs) in an Adolescent with Metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumour (IMT) - Katrina Ingle, University College Hospital, London
12:12 - 12:30	Questions and Discussion
12:30 - 13:30	Lunch and poster viewing
13:30 - 14:15	SESSION 4: What's new in medical oncology for sarcoma CHAIR: Ian Judson
13:30 - 13:47	What is exciting in preclinical and translational Sarcoma Research - Dr Paul Huang, Institute of Cancer Research
13:47 - 14:04	Recent systemic therapy advances in sarcomas - Prof Robin Jones, Royal Marsden Hospital
14:04 - 14:15	Questions and Discussion
14:20 - 15:05	SESSION 5: Radiology CHAIR: Andrew Hayes
14:20 - 14:37	Imaging response in localized sarcoma: the promise of AI - Dr Christina Messiou, Royal Marsden Hospital
14:37 - 14:54	Smart biopsy in sarcoma: new frontiers in image guided tumour targeting - Dr Ed Johnston, Royal Marsden Hospital
14:54 - 15:05	Questions and Discussion
15:05 - 15:15	Short afternoon break

15:15 - 16:00	SESSION 6: Proffered Papers - Service Improvement / Allied Health Professionals CHAIR: Owen Tilsley
15:15 - 15:22	The use of the instrumented gait analysis in the rehabilitation of gait and function following complex pelvic reconstructions secondary to sarcoma: A pilot study - Abby McCarthy, Royal National Orthopaedic Hospital
15:22 - 15:29	A review of functional milestones and use of tilt table following sacrectomy surgery - Isobel MacCallum, Royal National Orthopaedic Hospital
15:29 - 15:36	Sonographic standards in Musculoskeletal Oncology - Megan Scotcher, University Hospitals of Coventry and Warwickshire NHS Trust
15:36 - 15:43	Improving Early Diagnosis in Sarcomas in the UK - Bradley Price, Sarcoma UK
15:43 - 16:00	Questions and Discussion
16:00 - 16:40	SESSION 7: SPONSORED SESSION - Immedica CHAIR: Ioanna Nixon
	The management and treatment of Sarcoma during COVID 19 Dr Nasim Ali, The Clatterbridge Cancer Centre Dr Spyridon Gennatas, The Royal Marsden Hospital, London Questions and Discussion
16:40 - 16:45	Day One Round Up
	Mr Andrew Hayes, President, British Sarcoma Group
16:45	End of Day One

Conference Programme - Day Two: Thursday 25th February 2021

09:00 - 09:10	Welcome to Day Two Mr Andrew Hayes, President, BSG
09:10 - 09:55	SESSION 8: Local therapies: Radiotherapy CHAIR: Andrew Hayes
09:10 - 09:35	The Final results of the STRASS1 Trial - Dr Sylvie Bonvalot, Institute Curie, Paris
09:35 - 09:50	Relevance of STRASS1 for UK Practice - Dr Aisha Miah, Royal Marsden Hospital
09:50 - 09:55	Questions and Discussion
10:00 - 10:45	SESSION 9: Local therapies: Surgery CHAIR: Craig Gerrand
10:00 - 10:17	Multidisciplinary surgery for complex tumours at challenging sites - Mr Anant Desai, Queen Elizabeth University Hospital Birmingham
10:17 - 10:34	Patterns of treatment for Sarcoma in the UK. What we can learn from NCRAS - Dr Sandra Strauss, University College London Hospitals
10:34 - 10:45	Questions and Discussion
10:45 - 11:15	Morning break and poster viewing
11:15 - 12:15	SESSION 10: Proffered Papers - Surgery CHAIR: Andrew Hayes and Paul Cool
11:15 - 11:22	Incidence and survival of patients with retroperitoneal Sarcoma (RPS) diagnosed in England between 2013-2018: An analysis from PHE NCRAS demonstrating the impact of specialist services on outcome - Shane Collins, University College London/NCRAS (PHE)
11:22 - 11:29	Impact of Cumulative Burden of Postoperative Complications on Oncological Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma - Fabio Tirota, University Hospital Birmingham NHS Foundation Trust
11:29 - 11:36	Prognostic implications of histological organ involvement in retroperitoneal sarcoma - Robert Tyler, University Hospital Birmingham
11:36 - 11:43	Follow-up protocol after Marginal resection of non-coelomic Atypical Lipomatous Tumours/Well-differentiated Liposarcomas - Gausihi Sivarajah, The Royal Marsden NHS Foundation Trust
11:43 - 11:50	Objective analysis of functional muscle transfers in lower limb sarcoma - Steven Lo, Canniesburn Plastic Surgery Unit Glasgow
11:50 - 11:57	Outcomes of limb-threatening sarcomas compromising major vessels: a 15 year single-centre review - Alex Dearden, Newcastle Hospitals Trust
11:57 - 12:15	Questions and Discussion
12:15 - 12:30	Update on the BSG: the BSG AGM The BSG in the next decade - Mr Andrew Hayes, Consultant Surgeon, Royal Marsden Hospital and President, BSG
12:30 - 13:30	Lunch and poster viewing

13:30 - 14:15	SESSION 11: COVID 19 : New Models of Care in the wake of Coronavirus CHAIR: Adam Dangoor	13:00 - 16:00	National Sarcoma Forum
13:30 - 13:40	Virtual consultations and reducing risk during Covid – Dr Adam Dangoor, University Hospital Bristol	See NSF programme on the Conference website	
13:40 - 13:47	Remote consultations – Scotland – Dr Ioanna Nixon, Beatson West of Scotland Cancer Centre & Holly McCabe, The University of Strathclyde		
13:47 - 13:54	Remote consultations - Marsden - Allannah Smrke & Eugenie Younger		
13:54 - 14:01	Remote Prehab – Jane Masters, North Bristol Trust		
14:01 - 14:08	Virtual Home Visits – Danielle Birch, The Robert Jones and Agnes Hunt Orthopaedic Hospital Nhs Foundation Trust		
14:08 - 14:15	Questions and Discussion		
14:15 - 15:00	SESSION 12: Pathology CHAIR: Ian Judson		
14:15 - 14:32	Update on 5th edition of the WHO classification of STS Prof Adrienne Flanagan, Royal National Orthopaedic Hospital		
14:32 - 14:49	Interpretation and implementation of WGS for Sarcoma Dr Fernanda Amary, Royal National Orthopaedic Hospital		
14:49 - 15:00	Questions and Discussion		
15:00 - 15:10	Short afternoon break		
15:10 - 16:00	SESSION 13: SPONSORED SESSION - Bayer CHAIR: Adam Dangoor		
	Targeting NTRK fusions Prof Robin Jones, Royal Marsden Hospital Dr Adam Dangoor, University Hospital Bristol Questions and Discussion		
16:00 - 16:10	Closing remarks & prizes		
	Mr Andrew Hayes, President, BSG		
16:10	End of Conference		